LIXT vs TXT · $121.0M cap vs P/E 19, rev $7.52B
Lixte Biotechnology Holdings Inc (LIXT) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Lixte Biotechnology Holdings Inc (LIXT) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
LIXT does not have a complete income-statement cache yet.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
LIXT currently screens at market cap $121.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the LIXT and TXT stock pages for the full models.
Not investment advice.